These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22289989)

  • 21. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
    Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
    Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of acute myeloid leukemia cells.
    Li N; Jia X; Wang J; Li Y; Xie S
    Mol Med Rep; 2015 Nov; 12(5):6861-6. PubMed ID: 26397212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
    Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
    Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
    Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
    Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
    Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
    Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
    Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
    Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
    Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.
    Licciulli S; Cambiaghi V; Scafetta G; Gruszka AM; Alcalay M
    Leukemia; 2010 Feb; 24(2):429-37. PubMed ID: 20010624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.
    Pfister SX; Markkanen E; Jiang Y; Sarkar S; Woodcock M; Orlando G; Mavrommati I; Pai CC; Zalmas LP; Drobnitzky N; Dianov GL; Verrill C; Macaulay VM; Ying S; La Thangue NB; D'Angiolella V; Ryan AJ; Humphrey TC
    Cancer Cell; 2015 Nov; 28(5):557-568. PubMed ID: 26602815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.
    van Harten AM; de Boer DV; Martens-de Kemp SR; Buijze M; Ganzevles SH; Hunter KD; Leemans CR; van Beusechem VW; Wolthuis RMF; de Menezes RX; Brakenhoff RH
    Sci Rep; 2020 Feb; 10(1):2330. PubMed ID: 32047167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
    Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
    Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
    Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
    Yan H; Wen L; Tan D; Xie P; Pang FM; Zhou HH; Zhang W; Liu ZQ; Tang J; Li X; Chen XP
    Oncotarget; 2017 Jan; 8(1):1529-1540. PubMed ID: 27903973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285.
    Zhou Z; Zhong L; Chu X; Wan P; Dan W; Shao X; Chen S; Zhang Z; Lu Y; Liu B
    Med Oncol; 2023 Oct; 40(11):325. PubMed ID: 37805625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour suppressive effects of WEE1 gene silencing in neuroblastomas.
    Tashnizi AH; Jaberipour M; Razmkhah M; Rahnama S; Habibagahi M
    J Cancer Res Ther; 2016; 12(1):221-7. PubMed ID: 27072241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma.
    Bhattacharya A; Schmitz U; Wolkenhauer O; Schönherr M; Raatz Y; Kunz M
    Oncogene; 2013 Jun; 32(26):3175-83. PubMed ID: 22847610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
    Chen L; Hu N; Wang C; Zhao H
    Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.